Next Article in Journal
(10E,15Z)-12-(Dimethylsulfonio)-9,13-dihydroxyoctadeca-10,15-dienoate
Previous Article in Journal
3-(2-Chloroethoxy)-1-(4-methoxyphenyl)-1H-pyrazole-4-carbaldehyde
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Synthesis of (Z)-3-Allyl-5-(4-nitrobenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one and Determination of Its Crystal Structure

1
Institut UTINAM UMR 6213 CNRS, Université de Franche-Comté, 16, Route de Gray, 25030 Besançon, France
2
Laboratory of Heterocyclic Chemistry Natural Product and Reactivity (LR11ES39), Department of Chemistry, Faculty of Science of Monastir, University of Monastir, Monastir 5019, Tunisia
3
Anorganische Chemie, Technische Universität Dortmund, Otto-Hahn Straße 6, 44227 Dortmund, Germany
*
Authors to whom correspondence should be addressed.
Molbank 2024, 2024(1), M1783; https://doi.org/10.3390/M1783
Submission received: 14 February 2024 / Revised: 27 February 2024 / Accepted: 28 February 2024 / Published: 1 March 2024
(This article belongs to the Section Organic Synthesis)

Abstract

:
To extend the existing library of arylidenerhodanines which display a potential biological activity, 3-N-allylrhodanine 1 was condensed under Knoevenagel conditions with p-nitrobenzaldehyde in acetic acid to afford the π-conjugated heterocyclic compound 3-allyl-5-(4-nitrobenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one 2. Compound 2 was characterized by IR and NMR spectroscopy, and its UV-vis spectrum was compared with that of compound 3-allyl-5-(4-methoxybenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one 3. The molecular structure is ascertained by a single-crystal X-ray diffraction study performed at 100 K.

1. Introduction

The five-membered heterocyclic compound rhodanine, also called 2-thioxo-4-thiazolidinone (see Figure 1) and its derivatives [1] not only play a role in organic chemistry as building blocks for further transformations but have also found application in various therapeutic areas [2,3] due to their broad spectrum of biological and pharmacological activities. These include antidiabetic activity [4], protein kinase inhibitors [5,6], topoisomerase II inhibition potency [7,8], anticancer activity against MCF-7 breast cancer [9,10] and potential cholinesterase inhibitors [11,12]. After approval of the N-substituted rhodanine Epalrestat [13] by the Food and Drug Administration (FDA) as an inhibitor drug for the treatment of diabetic neuropathy [14], several arylidene N-substituted rhodanine derivatives have also been identified as potential inhibitors of essential therapeutic targets such as PTP1B [15], α-amylase [16] and α-glucosidase [17] for the clinical management of Type 2 diabetes mellitus (T2DM) (Figure 1). Very recently, we successfully synthesized a series of novel dispirooxindoles-based rhodanine derivatives as potent inhibitors against α-amylase enzyme with in vivo hypoglycemic activity [18].
Arylidene-functionalized rhodanines were also recently screened to evaluate their anticancer activity against several cancer cell lines [19,20] or their propensity as antibacterial, antifungal or antioxidants agents [21,22,23]. In this context, we have reacted a series of 4-arylidene-5-thioxo-thiazolidin-2-ones with the secondary cyclic amine tetrahydroisoquinoline (THIQ) to convert them to (Z)-5-ylidene-2-aminothiazol-4(5H)-ones [18]. Some selected compounds incorporating the rhodanine motive and displaying a pharmacological activity are presented in Figure 1.
Furthermore, rhodanine derivatives attracted the attention of coordination chemists, since the soft C=S thione function (according Pearson’s HSAB principle) [24] readily coordinates to a wide range of transition metal complexes producing complexes with Cu(I), Pd(II), Pt(II) etc. [25,26,27,28]. The research presented here is (i) a continuation of our investigations into the coordination chemistry of thione-type ligand on diverse metal centers [29,30,31,32,33] and (ii) the design of novel rhodanine-based scaffolds for probing their biological activities [18].

2. Results and Discussion

The hitherto unknown arylidene rhodanine derivate 3-allyl-5-(4-nitrobenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one 2 was obtained by addition of p-nitrobenzaldehyde to a solution of commercially available N-allylrhodanine 1 in acetic acid via a classical Knoevenagel condensation route [34] (Scheme 1). Note that the synthesis of an isomer of 2 bearing the NO2 group at the meta-position has been described by Ajlaoui et al. by the reaction of N-allylrhodanine 1 with (3-nitrobenzylidene)-4-methyl-5-oxopyrazolidin-2-ium ylide [35] and its NH analogue 5-(3-nitrobenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one has been isolated by Hesse using an L-proline-based deep eutectic solvent [22].
The structure of 2 was established using spectroscopic characterization and elemental analysis. On the infrared spectrum, an intense band at 1700 cm−1 is associated with the carbonyl group and the thiocarbonyl vibration is observed at 1217 cm−1. The NO stretching bands of the nitro group are located at 1509 and 1327 cm−1 and the ν(C=C) appear near 1590 cm−1 (see Figure S1). The 1H-NMR recorded in d6-DMSO (Figure 2) reveals the aryl signals as doublets at δ 7.91 and 8.36 ppm. The chemical shift in the vinyl proton at δ 7.93 indicates that the exocyclic double bond has a Z-configuration, as already observed for other 5-arylidene rhodanines described in the literature [6]. Its signal appears at a lower field than that of the E-isomer due to the stronger deshielding effect of the carbonyl group compared to the sulfur atom [36]. Four multiplets between 4.90–5.90 ppm are assigned to the allyl group. A pseudo doublet of triplet is present at δ 4.67 for the NCH2, resulting from 3J and 4J allylic couplings of 5.2 and 1.4 Hz, respectively. The terminal vinyl gives rise to two broad doublets of doublets at δ 5.17 and 5.21 ppm with trans and cis coupling across the double bond of 17.7 (H1H2) and 10.9 (H’1H2) Hz. The two doublets at δ 5.15 and 5.22 are broad with a small coupling of 1.2 Hz. These apparent quartets result from a 4J allylic coupling with H3 and a geminal 2J coupling between H1H’1s with similar values. (Figure 1). The proton-decoupled 13C NMR spectrum (Figure 3) reveals the presence of two signals at δ 193.2 and 166.9 ppm attributed to the thiocarbonyl and carbonyl groups of the rhodanine moiety. A resonance at δ 46.7 corresponds to NCH2, and olefinic carbon appears at 118.4 (C1) and 130.6 (C2, C7).
The UV-vis spectrum of highly π-conjugated 2 bearing a strongly electron-withdrawing NO2-group exerting a -M effect is shown in Figure 4. For comparison, we have also recorded the benzylidene derivative 3 bearing a MeO-group (+M effect) at the para-position of the aryl cycle [34]. This literature-known compound has been synthesized using the same experimental procedure described for 2 in 84% yield. The superposition of their UV-vis spectra reveals a bathochromic shift in the absorption bands for 2 compared to 3, indicating that the NO2-group causes a diminution in the energetic gap between the frontier orbitals HOMO-LUMO with respect to the methoxy group. The UV-vis spectra recorded in solvents of different polarity are shown in the Supplementary Materials as Figure S2. We tentatively attribute the adsorption bands presented in Table 1 as n-π* and π-π* transitions but exclude a push–pull effect despite the strong acceptor propensity of the p-nitro group.
To complete the characterization of this compound, we examined 2 crystallizing in the monoclinic space group P21/c by an X-ray diffraction study performed at 100 K. As shown in Figure 5, the two cycles linked through the C6=C7 double bond are almost coplanar including the nitro group (torsion angle: 5.81(5)°); the allyl substituent points out of this plane in a perpendicular manner (torsion angle C4N1C1C2 93.6°). The C8 atom of the six-membered benzylidene cycle and the S1 atom are cis-arranged with respect to the C6=C7 double bond. Overall, the structure resembles those of other benzylidenerhodanines found in the Cambridge Structural Database (CSD) such as 3-allyl-5-(3-methoxybenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one (refcod GACVOY) [37], 3-allyl-5-(4-fluorobenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one (refcod ISAMIA) [38], 3-allyl-5-(4-chlorobenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one (refcod JADVUI) [39] and 5-benzylidene-3-(prop-2-en-1-yl)-2-sulfanylidene-1,3-thiazolidin-4-one (refcod QIBKOE) [35]. Other crystallographically characterized N-allyl rhodanines containing five-membered heterocycles within their framework are 2-thio-3-allyl-5-(2-(3′methylthiazolidinylidene))-thiazolidine-2,4-dione (refcod SALAZO) [40] and (E)-3-Allyl-5-(2-thienylmethylene)-2-thioxo-1,3-thiazolidin-4-one (refcod MUGFUR) [41]. Particularly noteworthy is the occurrence of an intramolecular C-H··· S contact between the H9 atom attached at C9 of the aromatic cycle and S1 forming a pseudo-six-membered cycle with d(C-H ···S) 2.51 Å, with the angle C-H ···S being 133.4°. This kind of contact is also observed in the structures JADVUI (dC-H ···S 2.55 Å, angle 133°) and GACVOY (dC-H ···S 2.55 Å, angle 133°) [37].
In the packing (Figure 6), several secondary weak intermolecular interactions are present such as C-H contacts with the NO2 group of neighbored molecules (dC13-H13… O21 2.505(11) Å, angle 153.4°, symmetry code 11 + x, y,1 + z) and (dC3-H3B… O32 2.70(2) Å, angle 162.0°, symmetry code 21-x,1-y,-z). Furthermore, a shorter C-H ···O contact occurs with the carbonyl C=O (dC10-H10·····O11 2.4260(13) Å, angle 130.7°). An intermolecular C-H ···S contact occurs between a CH group of the allyl substituent and the thione function (dC2-H2·····S23 2.9259(5) Å, angle 144.0°, symmetry code 31 + x,1/2 − y, −1/2 + z). As observed for the p-chloro derivative [39], the cohesion of the crystal structure also is ensured by an π-π stacking interaction between individual molecules forming inversion dimers. The centroid-to-centroid separation between two stacked benzylidene rings amounts to 3.7986(12) Å (see Figure S3).
These interactions have also been assessed by means of a Hirshfeld surface analysis using the CrystalExplorer17 software (Figure 7) [43,44]. The Hirshfeld surface was mapped over dnorm in the range from –0.2156 to −1.1392 (arbitrary units). The corresponding fingerprints plots are presented in the Supplementary Materials (Figure S4).

3. Materials and Methods

All reagents were purchased from commercial suppliers and used as received. 1H and 13C NMR spectra were recorded on a Brucker AC 400 (Bruker, Wissembourg, France) spectrometer at 400 and 100 MHz, respectively. The infrared spectrum was recorded on a Vertex 70 spectrometer (Bruker, Wissembourg, France) in ATR mode. UV–Visible spectra were obtained on a VARIAN–Cary 300 array spectrophotometer (Varian, Melbourne, Australia). Elemental analyses were performed on a Thermo Fisher Flashsmart CHNS elemental analyzer.
A mixture of 3-allylrhodanine (1.73 g, 10 mmol), anhydrous sodium acetate (0.82 g, 10 mmol) and 4-nitrobenzaldehyde (1.90 g, 12.5 mmol) was refluxed in 10 mL of glacial acetic acid for 5 h. After cooling, yellow crystals were collected by filtration and washed with H2O (2 × 5 mL), EtOH (2 × 5 mL) and Et2O (5 mL). Yield: 95%. Anal. Calc. for C13H10N2O3S2 (M.W = 306.37 g.mol−1): C, 50.97; H, 3.29; N, 9.14; S, 20.93%. Found: C, 50.99; H, 3.38; N, 9.28; S, 20.87%. IR-ATR: 1700 ν(C=O), 1217 ν(C=S) cm−1. 1H NMR (DMSO-d6) at 298 K: δ 4.66 (td, 3J = 5.2, 4J = 1.4, 2H3, NCH2), 5.17 (dd, 3J = 17.7, J = 1.2, H1, =CH2), 5.21 (dd, 3J = 10.9, J = 1.2, H1′, =CH2), 5.85 (tdd, 3J = 17.7, 3J = 10.9, 4J = 5.2, H2, =CH), 7.91 (d, 3J = 8.82, 2H9, Ar-H), 7.93 (s, H7, =CH), 8.35 (d, 3J = 8.82, 2H10, Ar-H) ppm. 13C NMR (DMSO-d6) at 298 K: δ 46.7 (C3), 118.4 (C1), 124.9 (C9), 127.2 (C6), 130.5 and 130.6 (C7, C2), 132.0 (C10), 139.6 (C8), 148.2 (C11), 166.9 (C5), 193.2 (C4) ppm.
Since the grown single crystals of 2 used for the determination of the crystal structure were quite small, CuKα radiation was employed instead of MoKα radiation. A suitable crystal was mounted on an Bruker APEX-II CCD diffractometer Crystal data for C13H10N2O3S2: M = 306.35 g.mol−1, plate-shaped dark yellow crystals, crystal size 0.90 × 0.55 × 0.14 mm3, monoclinic, space group P21/c a = 7.8215(4) Å, b = 26.4778(17) Å, c = 7.1851(4) Å, α = 90°, β = 116.5790(10)°, γ = 90°, V = 1130.75(13) Å3, Z = 4, Dcalc = 1.529 g/cm3, T = 100 K, R1 = 0.0360, Rw2 = 0.0966 (all data) for 2726 reflections with I > = 2σ (I) and 2832 independent reflections, GOF = 1.060 Largest diff. peak/hole/e Å−3 0.406/−0.313. The structure was solved using intrinsic phasing and refined using full-matrix least-squares against F2 (SHELXT, SHELXL 2015) [45,46]. The data were collected using graphite-monochromated CuKα radiation l = 1.54178 Å and have been deposited at the Cambridge Crystallographic Data Centre as CCDC 2327984. (Supplementary Materials). The data can be obtained free of charge from the Cambridge Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/getstructures.

4. Conclusions

We have shown that arylidenerhodanine 2 is easily accessible in high yields and crystallographically evidenced that this π-conjugated heterocycle features both intra- and intermolecular secondary interactions. We are currently exploring the propensity of this compound to act as an S-donor ligand in coordination chemistry.

Supplementary Materials

CIF file, Check-CIF report, UV-Vis and IR spectra and Hirshfeld fingerprint plots. Figures S1–S4.

Author Contributions

B.M. prepared the compound; C.S. and T.S. collected the X-ray data and solved the structure; I.J., S.B. and M.K. designed the study and analyzed the data and wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Région Bourgogne-Franche-Comté, DeCOmAB project.

Data Availability Statement

The X-ray data are deposited at CCDC as stated in the paper.

Acknowledgments

We thank Stéphanie Beffy for recording the IR and NMR spectra and Abderrahim Khatyr for recording the UV-vis spectra.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Brown, F.C.; Bradsher, C.K.; Bond, S.M.; Potter, M. Rhodanine Derivatives. J. Am. Chem. Soc. 1951, 73, 2357–2359. [Google Scholar] [CrossRef]
  2. Kaminskyy, D.; Kryshchyshyn, A.; Lesyk, R. Recent Developments with Rhodanine as a Scaffold for Drug Discovery. Expert Opin. Drug Discov. 2017, 12, 1233–1252. [Google Scholar] [CrossRef]
  3. Mousavi, S.M.; Zarei, M.; Hashemi, S.A.; Babapoor, A.; Amani, A.M. A Conceptual Review of Rhodanine: Current Applications of Antiviral Drugs, Anticancer and Antimicrobial Activities. Artif. Cells Nanomed. Biotechnol. 2019, 47, 1132–1148. [Google Scholar] [CrossRef] [PubMed]
  4. Bin Ahmad Kamar, A.K.D.; Ju Yin, L.; Tze Liang, C.; Tjin Fung, G.; Avupati, V.R. Rhodanine Scaffold: A Review of Antidiabetic Potential and Structure–Activity Relationships (SAR). Med. Drug Discov. 2022, 15, 100131. [Google Scholar] [CrossRef]
  5. Naufal, M.; Hermawati, E.; Syah, Y.M.; Hidayat, A.T.; Hidayat, I.W.; Al-Anshori, J. Structure–Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review. ACS Omega 2024, 9, 4186–4209. [Google Scholar] [CrossRef] [PubMed]
  6. Bourahla, K.; Guihéneuf, S.; Limanton, E.; Paquin, L.; Le Guével, R.; Charlier, T.; Rahmouni, M.; Durieu, E.; Lozach, O.; Carreaux, F.; et al. Design and Microwave Synthesis of New (5Z) 5-Arylidene-2-Thioxo-1,3-Thiazolinidin-4-One and (5Z) 2-Amino-5-Arylidene-1,3-Thiazol-4(5H)-One as New Inhibitors of Protein Kinase DYRK1A. Pharmaceuticals 2021, 14, 1086. [Google Scholar] [CrossRef] [PubMed]
  7. Khodair, A.I.; Alzahrani, F.M.; Awad, M.K.; Al-Issa, S.A.; Al-Hazmi, G.H.; Nafie, M.S. Design, Synthesis, Computational Investigations, and Antitumor Evaluation of N-Rhodanine Glycosides Derivatives as Potent DNA Intercalation and Topo II Inhibition against Cancer Cells. ACS Omega 2023, 8, 13300–13314. [Google Scholar] [CrossRef]
  8. Jiang, H.; Zhang, W.-J.; Li, P.-H.; Wang, J.; Dong, C.-Z.; Zhang, K.; Chen, H.-X.; Du, Z.-Y. Synthesis and Biological Evaluation of Novel Carbazole-Rhodanine Conjugates as Topoisomerase II Inhibitors. Bioorg. Med. Chem. Lett. 2018, 28, 1320–1323. [Google Scholar] [CrossRef] [PubMed]
  9. Szczepański, J.; Tuszewska, H.; Trotsko, N. Anticancer Profile of Rhodanines: Structure–Activity Relationship (SAR) and Molecular Targets—A Review. Molecules 2022, 27, 3750. [Google Scholar] [CrossRef]
  10. Yin, L.J.; Bin Ahmad Kamar, A.K.D.; Fung, G.T.; Liang, C.T.; Avupati, V.R. Review of Anticancer Potentials and Structure-Activity Relationships (SAR) of Rhodanine Derivatives. Biomed. Pharmacother. 2022, 145, 112406. [Google Scholar] [CrossRef]
  11. Krátký, M.; Nováčková, K.; Svrčková, K.; Švarcová, M.; Štěpánková, Š. New 3-Amino-2-Thioxothiazolidin-4-One-Based Inhibitors of Acetyl- and Butyryl-Cholinesterase: Synthesis and Activity. Future Med. Chem. 2024, 16, 59–74. [Google Scholar] [CrossRef]
  12. Krátký, M.; Štěpánková, Š.; Vorčáková, K.; Vinšová, J. Synthesis and in Vitro Evaluation of Novel Rhodanine Derivatives as Potential Cholinesterase Inhibitors. Bioorg. Chem. 2016, 68, 23–29. [Google Scholar] [CrossRef] [PubMed]
  13. Available online: https://en.wikipedia.org/wiki/epalrestat (accessed on 9 February 2024).
  14. Hotta, N.; Sakamoto, N.; Shigeta, Y.; Kikkawa, R.; Goto, Y. Clinical Investigation of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Neuropathy in Japan: Multicenter Study. J. Diabetes Complicat. 1996, 10, 168–172. [Google Scholar] [CrossRef] [PubMed]
  15. Sun, L.; Wang, P.; Xu, L.; Gao, L.; Li, J.; Piao, H. Discovery of 1,3-Diphenyl-1H-Pyrazole Derivatives Containing Rhodanine-3-Alkanoic Acid Groups as Potential PTP1B Inhibitors. Bioorg. Med. Chem. Lett. 2019, 29, 1187–1193. [Google Scholar] [CrossRef] [PubMed]
  16. Bansal, G.; Singh, S.; Monga, V.; Thanikachalam, P.V.; Chawla, P. Synthesis and Biological Evaluation of Thiazolidine-2,4-Dione-Pyrazole Conjugates as Antidiabetic, Anti-Inflammatory and Antioxidant Agents. Bioorg. Chem. 2019, 92, 103271. [Google Scholar] [CrossRef] [PubMed]
  17. Wang, G.; Peng, Y.; Xie, Z.; Wang, J.; Chen, M. Synthesis, α-Glucosidase Inhibition and Molecular Docking Studies of Novel Thiazolidine-2,4-Dione or Rhodanine Derivatives. Med. Chem. Commun. 2017, 8, 1477–1484. [Google Scholar] [CrossRef] [PubMed]
  18. Toumi, A.; Boudriga, S.; Hamden, K.; Sobeh, M.; Cheurfa, M.; Askri, M.; Knorr, M.; Strohmann, C.; Brieger, L. Synthesis, Antidiabetic Activity and Molecular Docking Study of Rhodanine-Substitued Spirooxindole Pyrrolidine Derivatives as Novel α-Amylase Inhibitors. Bioorg. Chem. 2021, 106, 104507. [Google Scholar] [CrossRef]
  19. Dago, C.; Ambeu, C.; Coulibaly, W.-K.; Békro, Y.-A.; Mamyrbékova, J.; Defontaine, A.; Baratte, B.; Bach, S.; Ruchaud, S.; Guével, R.; et al. Synthetic Development of New 3-(4-Arylmethylamino)Butyl-5-Arylidene-Rhodanines under Microwave Irradiation and Their Effects on Tumor Cell Lines and against Protein Kinases. Molecules 2015, 20, 12412–12435. [Google Scholar] [CrossRef]
  20. Ali Muhammad, S.; Ravi, S.; Thangamani, A. Synthesis and Evaluation of Some Novel N-Substituted Rhodanines for Their Anticancer Activity. Med. Chem. Res. 2016, 25, 994–1004. [Google Scholar] [CrossRef]
  21. Akhavan, M.; Foroughifar, N.; Pasdar, H.; Bekhradnia, A. Green Synthesis, Biological Activity Evaluation, and Molecular Docking Studies of Aryl Alkylidene 2, 4-Thiazolidinedione and Rhodanine Derivatives as Antimicrobial Agents. Comb. Chem. High Throughput Screen. 2020, 22, 716–727. [Google Scholar] [CrossRef] [PubMed]
  22. Tomašić, T.; Zidar, N.; Mueller-Premru, M.; Kikelj, D.; Mašič, L.P. Synthesis and Antibacterial Activity of 5-Ylidenethiazolidin-4-Ones and 5-Benzylidene-4,6-Pyrimidinediones. Eur. J. Med. Chem. 2010, 45, 1667–1672. [Google Scholar] [CrossRef]
  23. Hesse, S. Synthesis of 5-Arylidenerhodanines in L-Proline-Based Deep Eutectic Solvent. Beilstein J. Org. Chem. 2023, 19, 1537–1544. [Google Scholar] [CrossRef] [PubMed]
  24. Pearson, R.G. Recent Advances in the Concept of Hard and Soft Acids and Bases. J. Chem. Educ. 1987, 64, 561. [Google Scholar] [CrossRef]
  25. Moers, F.G.; Bosman, W.P.J.H.; Beurskens, P.T. Crystal Structure of 3-Methylrhodaninecopper(I) Iodide. J. Cryst. Mol. Struct. 1972, 2, 23–29. [Google Scholar] [CrossRef]
  26. Moers, F.G.; Goossens, J.W.M.; Langhout, J.P.M. Rhodanine Complexes of Copper(I), Palladium(II) and Platinum(II). J. Inorg. Nucl. Chem. 1973, 35, 855–859. [Google Scholar] [CrossRef]
  27. Moers, F.G.; Smits, J.M.M.; Beurskens, P.T. Crystal Structure of Bis-(Rhodanine)Copper(I) Iodide, C6H6CuIN2O2S4. J. Crystallogr. Spectrosc. Res. 1986, 16, 101–106. [Google Scholar] [CrossRef]
  28. Fabretti, A.C.; Peyronel, G.; Franchini, G.C. Copper(I) Complexes of Rhodanine. Transit. Met. Chem. 1978, 3, 125–127. [Google Scholar] [CrossRef]
  29. Arar, W.; Khatyr, A.; Knorr, M.; Brieger, L.; Krupp, A.; Strohmann, C.; Efrit, M.L.; Ben Akacha, A. Synthesis, Crystal Structures and Hirshfeld Analyses of Phosphonothioamidates (EtO)2P(=O)C(=S)N(H)R (R = Cy, Bz) and Their Coordination on CuI and HgX2 (X = Br, I). Phosphorus Sulfur Silicon Relat. Elem. 2021, 196, 845–858. [Google Scholar] [CrossRef]
  30. Hameau, A.; Guyon, F.; Knorr, M.; Enescu, M.; Strohmann, C. Self-Assembly of Dithiolene-Based Coordination Polymers of Mercury(II): Dithioether versus Thiocarbonyl Bonding. Monatsh. Chem. 2006, 137, 545–555. [Google Scholar] [CrossRef]
  31. Guyon, F.; Hameau, A.; Khatyr, A.; Knorr, M.; Amrouche, H.; Fortin, D.; Harvey, P.D.; Strohmann, C.; Ndiaye, A.L.; Huch, V.; et al. Syntheses, Structures, and Photophysical Properties of Mono- and Dinuclear Sulfur-Rich Gold(I) Complexes. Inorg. Chem. 2008, 47, 7483–7492. [Google Scholar] [CrossRef]
  32. Hameau, A.; Guyon, F.; Khatyr, A.; Knorr, M.; Strohmann, C. 4,5-Bis(Methylthio)-1,3-Dithiole-2-Thione, a Versatile Sulphur-Rich Building Block for the Self-Assembly of Cu(I) and Ag(I) Coordination Polymers: Dithioether versus Thiocarbonyl Bonding. Inorg. Chim. Acta 2012, 388, 60–70. [Google Scholar] [CrossRef]
  33. Arar, W.; Viau, L.; Jourdain, I.; Knorr, M.; Strohmann, C.; Scheel, R.; Ben Akacha, A. Synthesis of Catena-Bis(μ-Bromo)-(O-Methyl-N-Phenylthiocarbamate)-Dicopper(I) and Its Reactivity towards PAr3 (Ar = Ph, p-Tol). Molbank 2023, 2023, M1655. [Google Scholar] [CrossRef]
  34. Gouveia, F.L.; De Oliveira, R.M.B.; De Oliveira, T.B.; Da Silva, I.M.; Do Nascimento, S.C.; De Sena, K.X.F.R.; De Albuquerque, J.F.C. Synthesis, Antimicrobial and Cytotoxic Activities of Some 5-Arylidene-4-Thioxo-Thiazolidine-2-Ones. Eur. J. Med. Chem. 2009, 44, 2038–2043. [Google Scholar] [CrossRef] [PubMed]
  35. El Ajlaoui, R.; Ouafa, A.; Mojahidi, S.; El Ammari, L.; Saadi, M.; El Mostapha, R. Unexpected Synthesis of Novel 3-Allyl-5-(Arylidene)-2-Thioxo-Thiazolidin-4-Ones in Reactions of 3-Allylrhodanine with 2-Arylidene-4-Methyl-5-Oxopyrazolidinium Ylides. Synth. Commun. 2015, 45, 2035–2042. [Google Scholar] [CrossRef]
  36. Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on Antidiabetic Agents. X. Synthesis and Biological Activities of Pioglitazone and Related Compounds. Chem. Pharm. Bull. 1991, 39, 1440–1445. [Google Scholar] [CrossRef]
  37. El Ajlaoui, R.; Rakib, E.M.; Mojahidi, S.; Saadi, M.; El Ammari, L. (Z)-3-Allyl-5-(3-Methoxybenzylidene)-2-Sulfanylidene-1,3-Thiazolidin-4-One. IUCrData 2016, 1, x160052. [Google Scholar] [CrossRef]
  38. El Ajlaoui, R.; Belkhouya, N.; Rakib, E.M.; Mojahidi, S.; Saadi, M.; El Ammari, L. (Z)-3-Allyl-5-(4-Fluorobenzylidene)-2-Sulfanylidenethiazolidin-4-one. IUCrData 2016, 1, x161236. [Google Scholar] [CrossRef]
  39. El Ajlaoui, R.; Rakib, E.M.; Mojahidi, S.; Saadi, M.; El Ammari, L. Crystal Structure of (Z)-3-Allyl-5-(4-Chlorobenzylidene)-2-Sulfanylidene-1,3-Thiazolidin-4-one. Acta Crystallogr. Sect. E Crystallogr. Commun. 2015, 71, o1012. [Google Scholar] [CrossRef]
  40. Germain, G.; Piret, P.; Van Meersche, M.; De Kerf, J. Structure d’une Mérocyanine: C10H12S3N2O. Acta Crystallogr. 1962, 15, 373–382. [Google Scholar] [CrossRef]
  41. El Ajlaoui, R.; Rakib, E.M.; Mojahidi, S.; Saadi, M.; El Ammari, L. Crystal Structure of (E)-3-Allyl-2-Sulfanylidene-5-[(Thiophen-2-Yl)Methylidene]Thiazolidin-4-one. Acta Crystallogr. Sect. E Crystallogr. Commun. 2015, 71, o433–o434. [Google Scholar] [CrossRef]
  42. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341. [Google Scholar] [CrossRef]
  43. Spackman, M.A.; Jayatilaka, D. Hirshfeld Surface Analysis. CrystEngComm 2009, 11, 19–32. [Google Scholar] [CrossRef]
  44. Spackman, P.R.; Turner, M.J.; McKinnon, J.J.; Wolff, S.K.; Grimwood, D.J.; Jayatilaka, D.; Spackman, M.A. CrystalExplorer: A Program for Hirshfeld Surface Analysis, Visualization and Quantitative Analysis of Molecular Crystals. J. Appl. Crystallogr. 2021, 54, 1006–1011. [Google Scholar] [CrossRef] [PubMed]
  45. Sheldrick, G.M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. C Struct. Chem. 2015, 71, 3–8. [Google Scholar] [CrossRef]
  46. Sheldrick, G.M. SHELXT—Integrated Space-Group and Crystal-Structure Determination. Acta Crystallogr. A Found Adv. 2015, 71, 3–8. [Google Scholar] [CrossRef]
Figure 1. Examples of some rhodanines displaying a biological activity.
Figure 1. Examples of some rhodanines displaying a biological activity.
Molbank 2024 m1783 g001
Scheme 1. Knoevenagel synthesis of N-allylrhodanine 2.
Scheme 1. Knoevenagel synthesis of N-allylrhodanine 2.
Molbank 2024 m1783 sch001
Figure 2. 1H NMR spectra (400 MHz, DMSO-d6) of compound 2 at 298 K.
Figure 2. 1H NMR spectra (400 MHz, DMSO-d6) of compound 2 at 298 K.
Molbank 2024 m1783 g002
Figure 3. 13C NMR spectra (100 MHz, DMSO-d6) of compound 2 at 298 K. The DMSO-d6 signal has been cut off.
Figure 3. 13C NMR spectra (100 MHz, DMSO-d6) of compound 2 at 298 K. The DMSO-d6 signal has been cut off.
Molbank 2024 m1783 g003
Figure 4. Superposition of the normalized absorption spectra recorded of 2 and 3 in CH2Cl2 at 298 K.
Figure 4. Superposition of the normalized absorption spectra recorded of 2 and 3 in CH2Cl2 at 298 K.
Molbank 2024 m1783 g004
Figure 5. Molecular structure of 2. Selected bond lengths (Å) and angles (deg) of 2. Apart from H7 and H9, all other H atoms are omitted for clarity. S1–C6 1.7536(16), S1–C4 1.7614(16), S2–C4 1.6227(16), N1–C4 1.375(2), N1–C1 1.472(2), C1–C2 1.375(2), C2–C3 1.314(3), N1–C5 1.388(2), C5–O12 1.217(2), C5–C6 1.487(2), C6–C7 1.346(2), C7–C8 1.458(2); C3–C2–C1 127.19(16), C2–C1–N1 113.87(14), C1–N1–C4 122.77(14), N1–C4–S2 127.50(13), N1–C4–S1 110.22(11), C4–S1–C6 92.80(8), S1–C6–C5 109.14(11), S1–C6–C7 130.41(12), C6–C5–N1 110.90(13), C6–C7–C8 130.11(14), O2–N2–O3 123.61(14).
Figure 5. Molecular structure of 2. Selected bond lengths (Å) and angles (deg) of 2. Apart from H7 and H9, all other H atoms are omitted for clarity. S1–C6 1.7536(16), S1–C4 1.7614(16), S2–C4 1.6227(16), N1–C4 1.375(2), N1–C1 1.472(2), C1–C2 1.375(2), C2–C3 1.314(3), N1–C5 1.388(2), C5–O12 1.217(2), C5–C6 1.487(2), C6–C7 1.346(2), C7–C8 1.458(2); C3–C2–C1 127.19(16), C2–C1–N1 113.87(14), C1–N1–C4 122.77(14), N1–C4–S2 127.50(13), N1–C4–S1 110.22(11), C4–S1–C6 92.80(8), S1–C6–C5 109.14(11), S1–C6–C7 130.41(12), C6–C5–N1 110.90(13), C6–C7–C8 130.11(14), O2–N2–O3 123.61(14).
Molbank 2024 m1783 g005
Figure 6. OLEX-generated view of the unit cell of 2 indicating the π—π stacking interaction between individual molecules [42].
Figure 6. OLEX-generated view of the unit cell of 2 indicating the π—π stacking interaction between individual molecules [42].
Molbank 2024 m1783 g006
Figure 7. View of the Hirshfeld surface of compound 2 revealing some loose contacts in the crystal structure.
Figure 7. View of the Hirshfeld surface of compound 2 revealing some loose contacts in the crystal structure.
Molbank 2024 m1783 g007
Table 1. Absorption data of compounds 2 and 3 in CH2Cl2 at 298 K.
Table 1. Absorption data of compounds 2 and 3 in CH2Cl2 at 298 K.
Comp.Absorption: λabs nm (ε × 10−3M−1cm−1)
2239 (5.5), 281 (6.7), 303 sh (4.8), 381 (17.9), 399 sh (16.0)
3242 (2.8), 262 (3.2), 294 (6.1), 313 sh (3.6), 399 (18.1)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Moreno, B.; Jourdain, I.; Knorr, M.; Boudriga, S.; Strohmann, C.; Schrimpf, T. Synthesis of (Z)-3-Allyl-5-(4-nitrobenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one and Determination of Its Crystal Structure. Molbank 2024, 2024, M1783. https://doi.org/10.3390/M1783

AMA Style

Moreno B, Jourdain I, Knorr M, Boudriga S, Strohmann C, Schrimpf T. Synthesis of (Z)-3-Allyl-5-(4-nitrobenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one and Determination of Its Crystal Structure. Molbank. 2024; 2024(1):M1783. https://doi.org/10.3390/M1783

Chicago/Turabian Style

Moreno, Bastien, Isabelle Jourdain, Michael Knorr, Sarra Boudriga, Carsten Strohmann, and Tobias Schrimpf. 2024. "Synthesis of (Z)-3-Allyl-5-(4-nitrobenzylidene)-2-sulfanylidene-1,3-thiazolidin-4-one and Determination of Its Crystal Structure" Molbank 2024, no. 1: M1783. https://doi.org/10.3390/M1783

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop